ArticleTranslational andrology and urology2026
Evaluation of human epidermal growth factor receptor 2 (HER2)-related genes revealed that HER2-antibody-drug conjugate (ADC) drugs confer clinical benefits to Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer patients.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) instillation as the first-line treatment for high-risk non-muscle invasive bladder cancer (HR-NMIBC). However, a substantial proportion of BCG-refractory patients progress to muscle-invasive bladder cancer (BCa), and effective bladder-sparing therapeutic options remain scarce for this population. This study aims to develop a transcriptome-based predictive model for identifying HR-NMIBC patients who may benefit from human epidermal growth factor receptor 2 (HER2)-targeted therapy following BCG treatment failure, and to validate its clinical feasibility. Methods: We conducted a retrospective analysis of HR-NMIBC cases treated with BCG over the past decade at our institution to investigate the association between HER2 expression and clinical outcomes. Public databases were interrogated to elucidate the mechanisms underlying BCG failure in HER2-overexpressing NMIBC. A HER2-related prognostic score (HRS) model was developed using bioinformatics approaches, with subsequent exploration of transcriptomic disparities between high-risk and low-risk subgroups. The therapeutic potential of HER2-targeted agents was further validated through Results: Real-world retrospective analysis revealed HER2 overexpression as an independent predictor of BCG failure in NMIBC patients. The HRS prognostic model, constructed through Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression analysis of HER2-high versus HER2-low subgroups, demonstrated superior clinical outcomes for low-risk patients via Kaplan-Meier analysis. Progression-free survival-time-dependent-receiver operating characteristic (PFS-time-dependent-ROC) curves exhibited robust sensitivity and specificity at 1-, 3-, and 5-year intervals. Preclinical validations in cellular and animal models showed promising therapeutic efficacy of HER2-targeted interventions. Conclusions: HER2 overexpression serves as an independent prognostic biomarker for BCG failure in HR-NMIBC. The HRS prognostic model effectively stratifies high-risk patients who may derive clinical benefit from HER2-targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.